Last reviewed · How we verify

Ketamine-Morphine

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule

Ketamine-Morphine is a fixed-dose combination that combines NMDA receptor antagonism (ketamine) with mu-opioid receptor agonism (morphine) to provide analgesia and anesthesia.

Ketamine-Morphine is a fixed-dose combination that combines NMDA receptor antagonism (ketamine) with mu-opioid receptor agonism (morphine) to provide analgesia and anesthesia. Used for Acute pain management in hospital settings, Perioperative analgesia and anesthesia.

At a glance

Generic nameKetamine-Morphine
Also known asKetamine pre and per operative, and morphine postoperative, Ketamine Hydrochloric, Pfizer Inc., US, Morphine Pfizer Inc., US
SponsorAssistance Publique - Hôpitaux de Paris
Drug classOpioid-NMDA antagonist combination
TargetNMDA receptor (ketamine); mu-opioid receptor (morphine)
ModalitySmall molecule
Therapeutic areaAnesthesia, Pain Management
PhaseFDA-approved

Mechanism of action

Ketamine acts as a non-competitive antagonist at NMDA receptors, blocking glutamate-mediated pain signaling and providing dissociative anesthesia. Morphine is a mu-opioid receptor agonist that provides opioid analgesia. The combination leverages synergistic analgesic and anesthetic effects while potentially reducing the required doses of each agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results